Earle A. Chiles Research Institute, Providence Cancer Institute, 4805 NE Glisan St., 2N35, Portland, OR, 97213, USA.
Curr Oncol Rep. 2022 Jul;24(7):951-960. doi: 10.1007/s11912-022-01265-5. Epub 2022 Mar 29.
Despite the efficacy of immune checkpoint blockade (ICB) immunotherapy, most cancer patients still develop progressive disease necessitating additional treatment options. One approach is ligation of the OX40 (CD134) costimulatory receptor which promotes T cell activation, effector function, and the generation of long-lived memory cells.
Numerous preclinical studies have demonstrated that OX40 agonists alone or in combination with ICB (e.g., anti-PD-1, anti-PD-L1, and anti-CTLA-4) augment anti-tumor immunity. In this review, we discuss the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.
尽管免疫检查点阻断 (ICB) 免疫疗法有效，但大多数癌症患者仍会出现疾病进展，需要额外的治疗选择。一种方法是连接 OX40（CD134）共刺激受体，促进 T 细胞激活、效应功能和产生长寿记忆细胞。
许多临床前研究表明，OX40 激动剂单独或与 ICB（例如抗 PD-1、抗 PD-L1 和抗 CTLA-4）联合使用可增强抗肿瘤免疫。在这篇综述中，我们讨论了 OX40 激动剂对 T 细胞功能的影响，以及 OX40 激动剂单独或与 ICB 联合用于晚期恶性肿瘤患者的治疗潜力。
